Supplementary Figure 1 from Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure 1: U266 cells were transiently transfected with 500 nM of small interfering RNA (siRNA) SMARTpool for IGF1R or nonspecific control duplexes (pool of four; Thermo Scientific Dharmacon) using the Cell Line Nucleofector Kit V Solution (Amaxa Biosystems, Cologne, Germany), program X-005. After collection, cells were plated in a 96 well plate (20000 cells/well) and 72 h MTT viability assay was performed. Western blot analysis 72 hr after transfection shows a decrease in IGF1R expression in the U266 cell line ( lower panel). For the MTT assay, control cells (transfected with non specific control) were treated with and without AZD8055 100 nM, 66% decrease in viability was observed in presence of AZD8055. Transfected cells (IGF1R knock out cells) were cultured with and without AZD8055 100 nM. IGF1R knockout cells show 39% decrease in viability compared to scramble control and the combination of IGF1R knock out and AZD8055 100 nM show a 78% decrease in viability compared to scramble control. This finding suggests that IGF1R knockout sensitizes to AZD8055 inhibition similar to IGF1R antibody.
Authors: Diana Cirstea, Loredana Santo, Teru Hideshima, Homare Eda, Yuko Mishima, Neeharika Nemani, Anuj Mahindra, Andrew Yee, Gullu Gorgun, Yiguo Hu, Hiroto Ohguchi, Rikio Suzuki, Francesca Cottini, Sylvie M. Guichard, Kenneth C. Anderson, Noopur Raje
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362534113